Source:http://linkedlifedata.com/resource/pubmed/id/16219009
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-10-12
|
pubmed:abstractText |
The usefulness of metformin as an oral antidiabetic agent is widely accepted. However, several other classes of oral antidiabetic agents have been recently introduced, raising the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs for treatment of type 2 diabetes mellitus (DM).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1462-8902
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
654-65
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading | |
pubmed:year |
2005
|
pubmed:articleTitle |
Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
|
pubmed:affiliation |
Department of Medicine and the Gonda (Goldschmied) Diabetes Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|